Table 1 Clinical features of C-Circle positive tumors in the screening cohort (n = 720)^a.

	Total cohort		C-Circle positive		C-Circle negative		P value^g
	No.^f	%^f	No. ^f	%^f	No.^f	%^f
Total	720		66	9.2%	654	90.8%
Stage 1-3^b	416	57.8%	25	37.9%	391	59.8%	1.948E-06
Stage 4^b	221	30.7%	41	62.1%	180	27.5%
Stage 4S^b	83	11.5%	0	0.0%	83	12.7%	0.000367
LR/IR^c	449	65.9%	24	36.9%	425	69.0%	6.944E-07
HR^c	232	34.1%	41	63.1%	191	31.0%
Male	397	55.1%	39	59.1%	358	54.7%	0.519
Female	323	44.9%	27	40.9%	296	45.3%
Age^d (mean in days)	871		2872		669		<2E-16
MYCN amp^e	114	16.2%	0	0.0%	114	17.9%	5.883E-06
MYCN normal^e	588	83.8%	66	100.0%	522	82.1%
Ganglioneuroma	11	1.5%	0	0.0%	11	1.7%	0.6115

^an refers to the number of tumors.
^bTumor staging was done according to the INSS criteria.
^cRisk stratification was based on the German Neuroblastoma Study NB2004. Risk stratification was not available for 39 tumors.
^dAge at diagnosis.
^eMYCN status refers to MYCN status at diagnosis, which is either amplified (amp, ≥8 copies) or normal. MYCN status was not available or inconclusive for 18 tumors.
^fAll values are given in absolute number of tumors (No.) and relative (%) to the total number of tumors in each group (total cohort, C-Circle positive, C-Circle negative).
^gP values were calculated using Fisher tests and two-sided Wilcoxon rank sum test (age).

Quick links

Search